
Mayville Engineering Company Completes Acquisition of Accu‑Fab, LLC
Accu-Fab is a vertically integrated manufacturing partner providing technology-driven, cutting-edge metal fabrication solutions to large OEMs. Accu-Fab offers value-added services that include design, engineering, sheet metal fabrication and integration, and specialized finishing. Through the acquisition of Accu-Fab, MEC enhances its strategic position by broadening its customer base and accelerating its entry into the rapidly growing critical power infrastructure and data center end markets. Leveraging MEC's broader geographic footprint, the combined business platform is well-positioned to meet rising demand within these end markets and significantly expands MEC's serviceable addressable market.
'The addition of Accu-Fab marks a significant milestone in our MBX value creation strategy,' said Jag Reddy, President and Chief Executive Officer. 'This immediately accretive acquisition, excluding transaction costs, enhances our presence in high-growth, mission-critical markets and expands our customer base in sectors with strong, long-term demand drivers. Our partnership with Accu-Fab brings together two high-performing teams with a shared focus on quality, service, and innovation. We anticipate a smooth integration and are excited about the long-term value we'll create for our customers and shareholders.'
ABOUT MAYVILLE ENGINEERING COMPANY
Founded in 1945, MEC is a leading U.S.-based, vertically-integrated, value-added manufacturing partner providing a full suite of manufacturing solutions from concept to production, including design, prototyping and tooling, fabrication, aluminum extrusion, coating, assembly and aftermarket components. Our customers operate in diverse end markets, including heavy- and medium-duty commercial vehicles, construction & access equipment, powersports, agriculture, military and other end markets. Along with process engineering and development services, MEC maintains an extensive manufacturing infrastructure with 23 facilities, of which 22 are in use, across seven states. These facilities make it possible to offer conventional and CNC (computer numerical control) stamping, shearing, fiber laser cutting, forming, drilling, tapping, grinding, tube bending, machining, welding, assembly, and logistic services. MEC also possesses a broad range of finishing capabilities including shot blasting, e-coating, powder coating, wet spray and military grade chemical agent resistant coating (CARC) painting. For more information, please visit www.mecinc.com.
FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements that reflect plans, estimates and beliefs. Such statements involve risk and uncertainties. Actual results may differ materially from those contemplated by these forward-looking statements as a result of various factors. Important factors that could cause actual results or events to differ materially from those expressed in forward-looking statements include, but are not limited to: macroeconomic conditions, including inflation, elevated interest rates, labor availability, material cost pressures and inconsistent demand, have had, and may continue to have, a negative impact on our business, financial condition, cash flows and results of operations (including future uncertain impacts); risks relating to developments in the industries in which our customers operate; risks related to scheduling production accurately and maximizing efficiency; our ability to realize net sales represented by our awarded business; failure to compete successfully in our markets; our ability to maintain our manufacturing, engineering and technological expertise; the loss of any of our large customers or the loss of their respective market shares; volatility in the prices or availability of raw materials critical to our business; geopolitical and economic developments, including foreign trade relations and associated tariffs; risks related to entering new markets; our ability to recruit and retain our key executive officers, managers and trade-skilled personnel; manufacturing risks, including delays and technical problems, issues with third-party suppliers, environmental risks and applicable statutory and regulatory requirements; our ability to successfully identify or integrate acquisitions; our ability to develop new and innovative processes and gain customer acceptance of such processes; risks related to our information technology systems and infrastructure; results of legal disputes, including product liability, intellectual property infringement and other claims; risks associated with our capital-intensive industry; risks related to our treatment as an S Corporation prior to the consummation of our initial public offering; risks related to our employee stock ownership plan's treatment as a tax-qualified retirement plan; our ability to remediate the material weakness in internal control over financial reporting identified in preparing our financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2024, and to subsequently maintain effective internal control over financial reporting; and other factors described in 'Risk Factors' in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2024, as such may be amended or supplemented in our subsequently filed Quarterly Reports on Form 10-Q. This discussion should be read in conjunction with our audited consolidated financial statements included in the Company's previously filed Annual Report on Form 10-K for the year ended December 31, 2024. We undertake no obligation to update or revise any forward-looking statements after the date on which any such statement is made, whether as a result of new information, future events or otherwise, except as required by federal securities laws.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
32 minutes ago
- Yahoo
Walmart (WMT) Holds Title as Largest Employer in the Dividend Aristocrats Index
Walmart Inc. (NYSE:WMT) is included among the 11 Best Dividend Aristocrat Stocks to Invest in Now. A manager standing in a hypermarket, pointing out items available for wholesale. The S&P Dividend Aristocrat Index includes companies with a wide range of workforce sizes, and Walmart Inc. (NYSE:WMT) stands out as the largest private employer in the US, with around 2.1 million employees. It also leads the index in revenue, having generated approximately $674 billion in the 12 months ending December 31, 2024, with a market capitalization of about $800 billion as of March 31, 2025. Walmart Inc. (NYSE:WMT)'s global store count declined from 11,501 at the end of fiscal 2020 to 10,593 by the end of fiscal 2022, mainly due to divestments in international markets. However, the company has since reversed that trend, closing fiscal 2025 with 10,711 stores worldwide. This steady growth in physical locations is expected to reinforce its competitive position and help it maintain an edge over smaller retail competitors. Walmart Inc. (NYSE:WMT) has been consistently raising its dividends for the past 52 years, which makes it one of the best dividend aristocrat stocks. The company's quarterly dividend comes in at $0.235 per share and has a dividend yield of 0.97%, as of June 27. While we acknowledge the potential of WMT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure. None.


Business Wire
34 minutes ago
- Business Wire
IntegraGen: Sales of €2.5 Million in the First Half of 2025 and Cash Position of €2.1 Million
EVRY, France--(BUSINESS WIRE)--Regulatory News: IntegraGen (FR0010908723 – ALINT – Eligible PEA PME), an OncoDNA company specializing in the genomics of cancer and rare genetic diseases, which performs interpretable genomic analyses for academic and private laboratories, announces today its unaudited sales for the first half of 2024. Sales for the first half came to €2,540K, down 34% compared with the first half of 2024 on a like-for-like basis (excluding revenues from the SeqOIA platform), contrary to expectations of weak growth, comparable to that of 2024, as announced by the Company in its press release dated April 29, 2025, on its results for the 2024 financial year. This decline is the result of reduced activity of over 40% on the Institut Pasteur's Mutualized Microbiology platform, linked to the drop in epidemiological sequencing, as well as to the decline in projects carried out on the Evry genomics platform, down by around 31%. This decline is the result of delays in the start-up of two major projects, the first samples of which were received by the company in May, as well as a general slowdown in research projects for academic and hospital customers. The company believes that the second half of the year, with the acceleration of major projects (notably UMBRELLA) and improved funding conditions for public research, should enable the situation to improve from the third quarter onwards. As of June 30 th, available cash, including the remainder on the loan granted to the parent company OncoDNA and repaid over the course of 2025, stood at €2.1m. The company used up €0.9m of cash in the first half of 2025, and at this rate may not have enough cash to ensure its financing for the next 12 months. In this context, the company is exploring all strategic options to improve its situation and expects to reduce cash consumption in the second half of the year through the reduction of operating costs, the launch of services for several existing customers, external sources of financing, a resumption of customer research projects, as well as the expected upturn in customers' research budgets. Given the high level of uncertainty surrounding public research funding, the Company is not maintaining its revenue growth forecasts for 2025. Bernard Courtieu, Chief Executive Officer of IntegraGen, comments: "The first half of the year has been extremely difficult, with both a sharp drop in academic and hospital research projects, linked to a reduction in public research financing, as well as a reduction in the budgets of several biotech companies in a sector affected by the general economic climate. Despite several successes such as the UMBRELLA project, whose operational launch was announced last month, IntegraGen needs to find new sources of funding to be able to ensure the continuity of its operations." Investors are invited to carefully read section 4.2 of the 2024 Management Report on 'Principal risks and uncertainties facing the Company'. Financial results for the first half of 2025 will be published in October. ABOUT INTEGRAGEN IntegraGen is an OncoDNA group company specializing in the genomics of cancer and rare genetic diseases. Backed by highly competent and qualified teams, IntegraGen is a leading player in DNA sequencing services and genomic data interpretation software. The company runs one of the largest NGS labs in France and operates for research institutes of excellence. As part of OncoDNA group, IntegraGen leverages the power of next generation sequencing with the mission of delivering the promise of precision medicine to patients. IntegraGen has about 40 employees and generated €8.5 million of turnover in 2024. Based in France, IntegraGen is part of the Belgian OncoDNA group present in Spain, UK, Germany and works with an international network of 35 distributors. The Group also provides biomarker testing and clinical interpretation tools to guide treatment and monitoring of late stage solid tumors and accelerate the development of new cancer drugs. IntegraGen is listed on Euronext Growth in Paris (ISIN: FR0010908723 – Mnemo: ALINT – Eligible PEA- PME).
Yahoo
35 minutes ago
- Yahoo
Why Oracle Stock Is Surging Today
Oracle is rising today after the company disclosed new growth figures and contract wins. The company says that MultiCloud revenue is still more than doubling annually, and it landed a new contract that will be worth more than $30 billion in annual sales. The stock is also rising thanks to positive coverage from analysts today. 10 stocks we like better than Oracle › Oracle (NYSE: ORCL) stock is seeing big gains in Monday's trading. The company's share price was up 4.6% as of 1:40 p.m. ET, amid a 0.2% gain for the S&P 500 (SNPINDEX: ^GSPC) and a 0.1% gain for the Nasdaq Composite (NASDAQINDEX: ^IXIC). The stock had been up as much as 8.6% earlier in the day. Oracle's valuation is climbing higher today following new guidance from management and bullish coverage from analysts. The reaction from investors has pushed the company's share price to a new all-time high. Oracle shared some major details about its outlook in the current fiscal year through a filing with the Securities and Exchange Commission (SEC), and investors are bidding up its stock in response. Through the filing, CEO Safra Catz said that the business was off to a strong start in its 2026 fiscal year, and noted that revenue for its MultiCloud database was continuing to grow at a rate greater than 100%. Even better, the company has recently inked a new deal that is expected to generate more than $30 billion in sales starting in its 2028 fiscal year. Before Oracle's SEC filing was made and before the market opened this morning, Stifel raised its rating on Oracle stock from hold to buy. Brad Reback, the firm's lead analyst on the stock, also raised his one-year price target on Oracle from $180 per share to $250 per share and pointed to ramping up capital expenditures and remaining performance obligations as signs that the company was making good on its targets in the cloud services space. Later in the day, Barclays weighed in with its own fresh coverage on the stock. The investment firm thinks that the growth and contract news contained in today's filing with the SEC will help allay investor concerns that the business won't be able to hit management's growth targets. The firm maintained an overweight rating on the stock and a one-year price target of $221 per share. As of this writing, Barclays' price target implies additional upside of just 0.5%. Meanwhile, Stifel's target suggests upside of roughly 14%. A strong rally has pushed the company's valuation to a new high, but big wins on the cloud front suggest that Oracle could still deliver wins for long-term investors. Before you buy stock in Oracle, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Oracle wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $713,547!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $966,931!* Now, it's worth noting Stock Advisor's total average return is 1,062% — a market-crushing outperformance compared to 177% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 30, 2025 Keith Noonan has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Oracle. The Motley Fool recommends Barclays Plc. The Motley Fool has a disclosure policy. Why Oracle Stock Is Surging Today was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data